1. Introduction {#sec1-molecules-14-03142}
===============

5-Fluorouracil (5-FU) is an antimetabolite of the pyrimidine analogue type, which is frequently used for treating solid tumors, such as colorectal, gastric tract, and liver carcinomas \[[@B1-molecules-14-03142],[@B2-molecules-14-03142],[@B3-molecules-14-03142]\]. However, the clinical applications of 5-FU are greatly limited by its short plasma half-life, poor tumor affinity, myelosuppression, and strong intestinal toxicity. Consequently, numerous research efforts have focused on the discovery of suitable carrier-linked prodrugs, in which 5-FU is conjugated with a wide spectrum of low- or high- molecular-weight carriers including glucose, peptides, and biodegradable polymers such as polysaccharides, liposomes, etc \[[@B4-molecules-14-03142],[@B5-molecules-14-03142],[@B6-molecules-14-03142],[@B7-molecules-14-03142],[@B8-molecules-14-03142],[@B9-molecules-14-03142],[@B10-molecules-14-03142]\]. In general prodrug systems the drug is bound to the carrier through a spacer that incorporates a predetermined breaking point that allows the bound drug to be released at the cellular target site. Therefore, the optimization physicochemical properties of a carrier, the modification of the carrier with 5-FU to preserve the targeting properties of the carrier and ensure a controlled release of 5-FU inside or outside the tumor cells are the critical aspects of 5-FU prodrug design \[[@B3-molecules-14-03142],[@B11-molecules-14-03142]\].

Peptides play an important role in human metabolism. Some peptide derivatives of 5-FU have been reported as an approach to develop chemotherapeutic agents with improved physicochemical and biological characteristics \[[@B4-molecules-14-03142],[@B12-molecules-14-03142],[@B13-molecules-14-03142]\], and we also have previously reported some peptide derivatives of 5-FU \[[@B14-molecules-14-03142],[@B15-molecules-14-03142],[@B16-molecules-14-03142]\]. In continuation of the research, we now describe our studies on the synthesis and assessment of some amino acid ester derivatives containing 5-FU with the aim of finding appropriate biodegradable linkages.

2. Results and Discussion {#sec2-molecules-14-03142}
=========================

2.1. Chemistry {#sec2dot1-molecules-14-03142}
--------------

The synthetic route to the target compounds **2a-o** is shown in [Scheme 1](#molecules-14-03142-sch001){ref-type="scheme"} and [Figure 1](#molecules-14-03142-f001){ref-type="fig"}. The starting material 2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl) acetic acid (or 5-fluorouracil-1-yl acetic acid) (**1**) could be easily prepared by carboxymethylation of 5-fluorouracil according to the literature \[[@B17-molecules-14-03142]\]. Treatment of compound **1** with a series of amino acid esters using 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC·HCl) and *N*-hydroxybenzotriazole (HOBt) as a coupling agent yielded a series of 2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-aceto amino acid ester derivatives **2**. HOBt was reported as a racemisation suppressant in peptide coupling reactions with carbodiimide coupling reagents \[[@B18-molecules-14-03142],[@B19-molecules-14-03142],[@B20-molecules-14-03142]\].

The purity and structures of compounds **2a-o** were established on the basis of their melting points, specific rotations and spectral data, which were in full agreement with the proposed molecular structures. The ^1^H-NMR spectra of all compounds showed doublets at 7.93-8.02 ppm, which corresponded to the coupling of fluorine and hydrogen signals in the FC=CH moieties. Compounds **2e-1** and **2e-2**, for example, almost have the same melting point (139-140 °C), the same spectral data, but opposite specfic rotations of $\left\lbrack \alpha \right\rbrack_{D}^{18.1}$−10.4 and $\left\lbrack \alpha \right\rbrack_{D}^{18.1}$+10.4, respectively. In the ^1^H-NMR their CH~2~SCH~3~ fragment methylene protons were observed as multiplets at δ 2.50-2.41 ppm, which overlapped with the signal of the solvent DMSO-*d*~6~. The ^13^C-NMR of **2c** and **2d** displayed signals at δ 39.7 ppm from the methylene carbon from the CH~2~CH(CH~3~)~2~ moiety which overlapped as well with that of the solvent DMSO-*d*~6~,. The assignment of the above four compounds were further proven by ^13^C-^1^H COSY spectra.

2.2. In vitro antitumor activity {#sec2dot2-molecules-14-03142}
--------------------------------

All target compounds **2a-o** were evaluated for their *in vitro* antitumor activity against the HL-60 leukaemia and BEL-7402 liver cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) \[[@B21-molecules-14-03142]\] and Sulforhodamine B (SRB) assay methods \[[@B22-molecules-14-03142]\], respectively, with 5-FU and the prodrug FT-207 being used for comparisons ([Table 1](#molecules-14-03142-t001){ref-type="table"} and [Table 2](#molecules-14-03142-t002){ref-type="table"}).

As shown in [Table 1](#molecules-14-03142-t001){ref-type="table"}, all compounds' *in vitro* inhibition rates against HL-60 were significantly lower than that of 5-FU, except for the R-type compounds **2h**, **2j**, **2k-2** and **2m**, which exhibited equivalent inhibitory effect as 5-FU at 10^-4^ mol/L concentration, but the activity decreased rapidly when the concentration declined. The results indicate that these compounds were less sensitive to HL-60 at lower concentrations when the *N*-1 position of 5-FU was occupied.

In [Table 2](#molecules-14-03142-t002){ref-type="table"}, almost all the compounds showed less sensitivity to BEL-7402, except **2m**, which showed more potent inhibitory effect than 5-FU. The reason maybe was the *R*-conformation of **2m** with a moderately rigid stereo structure, being composed of the pyrimidine ring and the phenyl ring, so it could release 5-FU sufficiently, while other compounds showed either more flexible configurations (such as **2a-e**), or a more rigid structure such as the case of **2k** \[[@B23-molecules-14-03142]\]. The different inhibition against HL-60 and BEL-7402 between *R*-type and *S*-type compounds suggested the complexity of the antitumor mechanism.

3. Experimental {#sec3-molecules-14-03142}
===============

3.1. General {#sec3dot1-molecules-14-03142}
------------

Melting points of synthesized compounds were determined on a Digital Melting Point Appatatus X-4 and were uncorrected. Mass spectra were obtained on a DECAX-30000 LCQ DecaXP Plus instrument. IR spectra were recorded (in KBr) on a Bruker EQUINOX 55. ^1^H-NMR and ^13^C-NMR were recorded on Bruker AVANCE-300 at 300 and 75 MHz, respectively in DMSO-*d*~6~ solutions with TMS as internal standard.

3.2. General procedure for the synthesis of compounds ***2a-o*** {#sec3dot2-molecules-14-03142}
----------------------------------------------------------------

Synthesis of compounds **2a-o** was accomplished as shown in [Scheme 1](#molecules-14-03142-sch001){ref-type="scheme"}. 2-(5-Fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl) acetic acid (10 mmol), HOBt (10 mmol) and DMF (50 mL) were added to a round-bottom flask, then EDC·HCl (13 mmol), L- or D-amino acid ester hydrochloride (10 mmol), and triethylamine (20 mmol) were added to the above mixture. After 10 h reaction at room temperature with thin layer chromatography (TLC) monitoring, the white solid 5-fluorouracil-1-yl-aceto amino acid esters **2a-o** were obtained after filtration, reduced pressure distillation of DMF, and silica gel column chromatography separation.

*(S)-Methyl 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-3-methylbutanoate* (**2a**). Yield: 68%; m.p. 109-110°C; ^1^H-NMR *δ*: 11.80 (s, 1H, NH of 5-FU), 8.54 (d, 1H, NH, *J* = 8.1 Hz), 8.01 (d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.39 (d, 2H, NCH~2~, *J* = 16.8 Hz), 4.22 (t, 1H, NCH, *J* = 7.2 Hz), 3.65 (s, 3H, OCH~3~), 2.09-1.98 (m, 1H, CCH, *J* = 6.6 Hz), 0.89 (d, 3H, CH~3~, *J* = 6.6 Hz), 0.87 (d, 3H, CH~3~, J = 6.6 Hz); ^13^C-NMR *δ*: 171.9, 167.1, 157.7(d, ^2^*J*~FC~ = 25.6 Hz), 149.8, 139.3 (d, ^1^*J*~FC~ = 226.7 Hz), 131.3 (d, ^2^*J*~FC~ = 33.6 Hz), 57.7, 51.9, 49.5, 30.4, 19.0, 18.3; IR (cm^-1^) *ν*: 3456, 3280, 2969, 1722, 1666, 1560, 1467, 1379, 1227, 1146, 783; MS (ESI) *m/z*: 300 (M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{10.0}$ -22.0 (*c* 1.0, DMF).

(*R*)-*Ethyl 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-3-methylbutanoate* (**2b**). Yield: 65%; m.p. 136-137 °C; ^1^H-NMR *δ*: 11.83(s, 1H, NH of 5-FU), 8.53 (d, 1H, NH, *J* = 8.1 Hz), 8.02 (d, 1H, FC=CH, ^3^*J*~FH~ = 6.6 Hz), 4.38 (d, 2H, NCH~2~, *J* = 16.8 Hz), 4.19 (dd, 1H, NCH, *J* = 8.1, 6.3 Hz), 4.16-4.05 (m, 2H, COOCH~2~, *J* = 7.2 Hz), 2.11-1.98 (m, 1H, CCH), 1.19 (t, 3H, OCH~2~C[H]{.ul}~3~, *J* = 7.2 Hz), 0.89 (d, 3H, CH~3~, *J* = 6.9 Hz), 0.88 (d, 3H, CH~3~, *J* = 6.6 Hz); ^13^C-NMR *δ*: 174.0, 169.6, 160.5 (d, ^2^*J*~FC~ = 25.3 Hz), 151.6, 141.2 (d, ^1^*J*~FC~ = 228.1 Hz), 132.8 (d, ^2^*J*~FC~ = 33.5 Hz), 63.3, 59.9, 51.6; 31.6, 20.0, 19.2, 15.2; IR (cm^-1^) *ν*: 3295, 3253, 2977, 1707, 1552, 1467, 1377, 1225, 1148; MS (ESI) *m*/*z*: 314(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{18.0}$+14.0 (*c* 0.1, DMF).

(*S*)-*Methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-4-methylpentanoate* (**2c**). Yield: 75%; m.p. 144-145°C; ^1^H-NMR *δ*: 11.83 (d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.4 Hz), 8.60 (d, 1H, NH, *J* = 7.8 Hz), 8.02 (d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.32 (s, 2H, NCH~2~), 4.35-4.27 (m, 1H, NCH), 3.62 (s, 3H, OCH~3~), 1.66-1.59 (m, 1H, CCH), 1.54-1.46 (m, 2H, CCH~2~), 0.88 (d, 3H, CH~3~, *J* = 6.3 Hz), 0.83 (d, 3H, CH~3~, *J* = 6.3 Hz); ^13^C-NMR *δ* 172.9, 167.0, 157.8 (d, ^2^*J*~FC~ = 25.5 Hz), 149.8, 139.4 (d, ^1^*J*~FC~ = 226.6 Hz), 131.3 (d, ^2^*J*~FC~ = 33.8 Hz), 52.2, 50.5, 49.6, 39.7, 24.3, 22.9, 21.6; IR (cm^-1^) *ν*: 3323, 3046, 2959, 1666, 1543, 1472, 1384, 1244, 1155; MS (ESI) *m/z*: 314(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{16.1}$-19.2 (*c* 1.0, DMF).

(*R*)-*Ethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-4-methylpentanoate* (**2d**). Yield: 72%; m.p. 146-147°C; ^1^H-NMR *δ*: 11.81(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.1 Hz), 8.57(d, 1H, NH, *J* =7.8 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.32(s, 2H, NCH~2~), 4.30-4.24(m, 1H, NCH), 4.08(q, 2H, OCH~2~, *J* = 7.2 Hz), 1.67-1.58(m, 1H, CCH), 1.56-1.48(m, 2H, CCH~2~), 1.17(t, 3H, OCH~2~CH~3~, *J* = 7.2 Hz), 0.89(d, 3H, CH~3~, *J* = 6.3 Hz), 0.84(d, 3H, CH~3~, *J* = 6.3 Hz); ^13C^-NMR(75 MHz) *δ*: 172.3, 166.8, 157.7(d, ^2^*J* ~FC~ = 25.2 Hz), 149.7, 139.3(d, ^1^*J*~FC~ = 226.4 Hz), 131.2 (d, ^2^*J*~FC~ = 33.9 Hz), 60.7, 50.6, 49.5, 39.7, 24.3, 22.8, 21.5, 14.1; IR(KBr, cm^-1^) *ν*: 3328, 2963, 2818, 1690, 1637, 1555, 1473, 1377, 1238, 1196, 1150; MS(ESI) *m/z*: 328(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.7}$+11.6(*c* 1.0, DMF).

(*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-4-(methylthio)butanoate (**2e-1**). Yield: 62%; m.p. 139-140°C; ^1^H-NMR(300 MHz) *δ*: 11.84(s, 1H, NH of 5-FU), 8.64(d, 1H, NH, *J* = 7.5 Hz), 8.02(d, 1H, FC=CH, ^3^*J* = 6.9 Hz), 4.46-4.39(m, 1H, NCH), 4.33(s, 2H, NCH~2~), 3.63(s, 3H, OCH~3~), 2.50-2.48(m, 2H, CH~2~S), 2.02(s,3H, SCH~3~), 1.97-1.79(m, 2H, CCH~2~); ^13^C-NMR(75 MHz) *δ*: 172.2, 167.1, 157.8(d, ^2^*J*~FC~ = 25.7 Hz), 149.9, 139.5(d, ^1^*J*~FC~ = 226.5 Hz), 131.2(d, ^2^*J*~FC~ = 33.8 Hz), 52.3, 51.1, 49.7, 30.9, 29.5, 14.8; IR(KBr, cm^-1^) *ν*: 3345, 3042, 2983, 1687, 1662, 1542, 1474, 1428, 1386, 1233; MS(ESI) *m/z*: 332(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{18.1}$-10.4(*c* 1.0, DMF).

(*R*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-4-(methylthio)butanoate (**2e-2**). Yield: 59%; m.p. 138-140 °C; ^1^H-NMR(300 MHz) *δ*: 11.83(s, 1H, NH of 5-FU), 8.63(d, NH, *J* = 7.6 Hz), 8.02(d, 1H, FC=CH, ^3^*J*~FH~ = 6.0 Hz), 4.43-4.38(m, 1H, NCH), 4.33(s, 2H, NCH~2~), 3.64(s, 3H, OCH~3~), 2.47-2.43(m, 2H, CH~2~S), 2.03(s, 3H, SCH~3~), 1.95-1.87(m, 2H, CCH~2~); ^13C-NMR^(75 MHz) *δ*: 172.1, 167.1, 157.8(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.5(d, ^1^*J*~FC~ = 226.7 Hz), 131.2 (d, ^2^*J*~FC~ = 33.7 Hz), 52.3, 51.1, 49.6, 30.9, 29.5, 14.7; IR(KBr, cm^-1^) *ν*: 3348, 3237, 2962, 1725, 1660, 1569, 1478, 1425, 1381, 1345, 1305, 1246, 1162, 794; MS(ESI) *m/z*: 332(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{18.1}$+10.4(*c* 1.0, DMF).

(*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-hydroxypropanoate (**2f-1**). Yield: 54%; m.p. 190-191°C; ^1^H-NMR(300 MHz) *δ*: 11.83(d, 1H, NH of 5-FU, ^4^*J*~HH~ = 4.5 Hz), 8.63(d, 1H, NH, *J* = 8.1 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 5.11(t, 1H, OH, *J* = 5.4 Hz), 4.38(s, 2H, NCH~2~), 4.42-4.36(m, 1H, NCH), 3.65(s, 3H, OCH~3~), 3.75-3.58(m, 2H, C[H]{.ul}~2~OH, *J* = 5.4, 10.8 Hz); ^13C-NMR^(75 MHz) *δ*: 170.9, 167.0, 157.6(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.3(d, ^1^*J*~FC~ = 226.7 Hz), 131.2(d, ^2^*J*~FC~ = 33.7 Hz), 61.4, 54.8, 52.0, 49.4; IR(KBr, cm^-1^) *ν*: 3459, 3295, 2850, 1713, 1692, 1563, 1467, 1416, 1382, 1277, 1251, 1185, 1071; MS(ESI) *m*/*z*: 288(M^-^). $\left\lbrack \alpha \right\rbrack_{D}^{10.7}$-10.0 (*c* 1.0, DMF).

*(R)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)-3-hydroxypropanoate* (**2f-2**). Yield: 55%; m.p. 190-192°C; ^1^H-NMR(300 MHz) *δ*: 11.81(s, 1H, NH of 5-FU), 8.62(d, 1H, NH, *J* = 7.5 Hz), 8.00(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 5.12(t, 1H, OH, *J* = 5.4 Hz), 4.37(s, 2H, NCH~2~), 4.41-4.35(m, 1H, NCH), 3.63(s, 3H, OCH~3~), 3.74-3.56(m, 2H, C[H]{.ul}~2~OH, *J* = 5.4, 10.8 Hz); ^13C-NMR^(75 MHz) *δ*: 171.0, 167.0, 157.7(d, ^2^*J*~FC~ = 25.6 Hz), 149.8, 139.3(d, ^1^*J*~FC~ = 226.6 Hz), 131.4(d, ^2^*J*~FC~ = 33.5 Hz), 61.5, 54.9, 52.1, 49.5; IR(KBr, cm^-1^) *ν*: 3459, 3295, 2850, 1713, 1692, 1563, 1467, 1416, 1382, 1277, 1251, 1185, 1071; MS(ESI) *m/z*: 288(M^-^). $\left\lbrack \alpha \right\rbrack_{D}^{11.0}$+10.0 (*c* 1.0, DMF).

(*S*)-dimethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)succinate (**2g**). Yield: 65%; m.p. 145-147 °C; ^1^H-NMR(300 MHz) *δ*: 11.85(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.1 Hz), 8.76(d, 1H, NH, *J* =7.8 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.6 Hz), 4.68(dd, 1H, NCH, *J* =7.5, 6.6 Hz), 4.33(s, 2H, NCH~2~), 3.64(s, 3H, OCH~3~), 3.62(s, 3H, OCH~3~), 2.85-2.70(m, 2H, CCH~2~, *J* = 6.6, 7.5, 16.8 Hz); ^13C-NMR^(75 MHz) *δ*: 170.9, 170.5, 166.9, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.4(d, ^1^*J*~FC~ = 228.0 Hz), 131.1 (d, ^2^*J*~FC~ = 33.9 Hz), 52.4, 51.9, 49.5, 48.7, 35.9; IR(KBr, cm^-1^) *ν*: 3348, 3191, 2850, 1755, 1697, 1526, 1430, 1380, 1337, 1216, 1047, 980; MS(ESI) *m/z*: 330(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{11.0}$-14.4(*c* 1.0, DMF).

(*R*)-diethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)succinate (**2h**). Yield: 68%; m.p. 116-118 °C; ^1^H-NMR(300 MHz) *δ*: 11.82(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 4.8 Hz), 8.71(d, 1H, NH, *J* = 7.8 Hz), 7.99(d, 1H, FC=CH, ^3^*J*~FH~ = 6.8 Hz), 4.63(dd, 1H, NCH, *J* = 6.6, 7.5 Hz), 4.33(s, 2H, NCH~2~), 4.12-4.03(m, 4H, OCH~2~, *J* = 6.9 Hz), 2.81-2.65(m, 2H, CCH~2~, *J* = 6.6, 16.5 Hz), 1.17(t, 3H, CH~3~, *J* = 6.9 Hz), 1.16(t, 3H, CH~3~, *J* = 6.9 Hz); ^13C-NMR^(75 MHz) *δ*: 170.4, 170.0, 166.9, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.4(d, ^1^*J*~FC~ = 228.3 Hz), 131.2 (d, ^2^*J*~FC~ = 33.8 Hz), 61.2, 60.6, 49.5, 48.9, 36.1, 14.2, 14.1; IR(KBr, cm^-1^) *ν*: 3314, 3217, 2990, 1721, 1691, 1549, 1467, 1378, 1339, 1240, 1167, 1021, 792; MS(ESI) *m/z*: 358(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{9.7}$+16.0 (*c* 1.0, DMF).

(*S*)-dimethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)pentanedioate (**2i**). Yield: 42%; m.p. 147-148 °C; ^1^H-NMR(300 MHz) *δ*: 11.85(s, 1H, NH of 5-FU), 8.63(d, 1H, NH, *J* =7.8 Hz), 8.02(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.32(s, 2H, NCH~2~), 4.37-4.34(m, 1H, NCH), 3.63(s, 3H, OCH~3~), 3.58(s, 3H, OCH~3~), 2.37(t, 2H, CH~2~C[H]{.ul}~2~CO, *J* = 7.5 Hz), 2.06-1.76(m, 2H, C[H]{.ul}~2~CH~2~CO); ^13C-NMR(75\ MHz)^ *δ*: 172.7, 171.9, 168.0, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.4(d, ^1^*J*~FC~ = 226.7 Hz), 131.1(d, ^2^*J*~FC~ = 33.7 Hz), 52.2, 51.5, 51.3, 49.6, 29.6, 26.4; IR(KBr, cm^-1^) *ν*: 3328, 2964, 1716, 1660, 1541, 1449, 1348, 1261, 800; MS(ESI) *m/z*: 344(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.8}$-8.39 (*c* 0.5, DMF).

(*R*)-diethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)pentanedioate (**2j**). Yield: 45%; m.p. 108-109 °C; ^1^H-NMR(300 MHz) *δ*: 11.84(s, 1H, NH of 5-FU), 8.61(d, 1H, NH, *J* = 7.8 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.33(s, 2H, NCH~2~), 4.30-4.26(m, 1H, NCH), 4.08(q, 2H, OC[H]{.ul}~2~CH~3~, *J* = 6.9 Hz), 4.04(q, 2H, OC[H]{.ul}~2~CH~3~, *J* = 7.2 Hz), 2.36(t, 2H, CH~2~C[H]{.ul}~2~CO, *J* = 7.5 Hz), 2.03-1.78(m, 2H, C[H]{.ul}~2~CH~2~CO), 1.17(t, 3H, OCH~2~C[H]{.ul}~3~, *J* = 6.9 Hz), 1.16(t, 3H, OCH~2~C[H]{.ul}~3~, *J* = 7.2 Hz); ^13C-NMR(75\ MHz)^ *δ*: 172.2, 171.4, 167.0, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.4(d, ^1^*J*~FC~ = 226.9 Hz), 131.2(d, ^2^*J*~FC~ = 33.7 Hz), 60.9, 60.1, 51.5, 49.6, 29.9, 26.5, 14.2, 14.1; IR(KBr, cm^-1^) *ν*: 3304, 3213, 2924, 1725, 1675, 1546, 1468, 1416, 1379, 1250, 1176, 1023; MS(ESI) *m/z*: 372 (M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{8.7}$+12.40 (*c* 1.0, DMF).

(*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-(1*H*-indol-3-yl)pro-panoate (**2k-1**). Yield: 50%; m.p. 205-206 °C; ^1^H-NMR(300 MHz) *δ*: 11.84(s, 1H, NH of 5-FU), 10.90(s, 1H, NH of indole), 8.72(d, 1H, NH, *J* = 7.2 Hz), 7.93(d, 1H, FC=CH, ^3^*J*~FH~ = 6.8 Hz), 7.48(d, 1H, Ar-H, *J* = 7.5 Hz), 7.33(d, 1H, Ar-H, *J* = 8.1 Hz), 7.16(d, 1H, =CHN, *J* = 2.2 Hz), 7.07(t, 1H, Ar-H, *J* = 8.1, 6.9 Hz), 6.99(t, 1H, Ar-H, *J* = 7.5, 6.9 Hz), 4.54(dd, 1H, NCH, *J* = 7.2, 6.6 Hz), 4.33(d, 2H, NCH~2~, *J* = 16.5 Hz), 3.56(s, 3H, OCH~3~), 3.19-3.03(m, 2H, CCH~2~, *J* = 7.5, 6.0, 14.4 Hz); ^13C-NMR^(75 MHz) *δ*: 172.2, 166.9, 157.8(d, ^2^*J*~FC~ = 25.7 Hz), 149.9, 139.4(d, ^1^*J*~FC~ = 228.1 Hz), 136.3, 131.3(d, ^2^*J*~FC~ = 33.8 Hz), 127.3, 124.1, 121.2, 118.7, 118.2, 111.7, 109.2, 53.6, 52.1, 49.5, 27.4; IR(KBr, cm^-1^) *ν*: 3386, 3312, 3069, 2977, 1702, 1545, 1381, 1233, 1062; MS(ESI) *m/z*: 387(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.9}$+36.4 (*c* 1.0, DMF).

(*R*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-(1*H*-indol-3-yl)pro-panoate (**2k-2**). Yield: 53%; m.p. 205-206 °C; ^1^H-NMR(300 MHz) *δ*: 11.84(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.1 Hz), 10.90(s, 1H, NH of indole), 8.72(d, 1H, NH, *J* = 7.5 Hz), 7.93(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 7.48(d, 1H, Ar-H, *J* = 7.8 Hz), 7.34(d,1H, Ar-H, *J* = 8.1 Hz), 7.16(s, 1H, =CHN), 7.07(t, 1H, Ar-H, *J* = 7.2, 7.8 Hz), 6.99(t, 1H, Ar-H, *J* = 7.2 Hz), 4.55(dd, 1H, NCH, *J* = 6.9, 6.6 Hz), 4.33(d, 2H, NCH~2~, *J* = 16.5 Hz), 3.57(s, 3H, OCH~3~), 3.20-3.03(m, 2H, CCH~2~, *J* = 7.5, 6.0, 14.8 Hz); ^13C-NMR^(75 MHz) *δ*: 172.2, 166.9, 157.8 (d, ^2^*J*~FC~ = 25.7 Hz), 149.9, 139.4(d, ^1^*J*~FC~ = 228.2 Hz), 136.3, 131.3(d, ^2^*J*~FC~ = 33.8 Hz), 127.3, 124.1, 121.2, 118.7, 118.2, 111.7, 109.2, 53.5, 52.1, 49.5, 27.4; IR(KBr, cm^-1^) *ν*: 3392, 3320, 3075, 1732, 1648, 1542, 1446, 1385, 1355, 1248, 1219,1099, 744; MS(ESI) *m/z*: 387(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.8}$-36.4 (*c* 1.0, DMF).

(*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-(4-hydroxyphenyl) propanoate (**2l**). Yield: 72%; m.p. 192-193 °C; ^1^H-NMR(300 MHz) *δ*: 11.85(s, 1H, NH of 5-FU), 9.28(s, 1H, OH), 8.68(d, 1H, NH, *J* = 7.5 Hz), 7.94(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 6.99 (d, 2H, Ar-H, *J* = 8.4 Hz), 6.66 (d, 2H, Ar-H, *J* = 8.4 Hz), 4.39(dd, 1H, NCH, *J* = 6.3, 7.5 Hz), 4.31(d, 2H, NCH~2~, *J* = 16.8 Hz), 3.59(s, 3H, OCH~3~), 2.93-2.77(m, 2H, CH~2~Ar, *J* = 6.3, 8.1, 13.8 Hz); ^13^C-NMR(75 MHz) *δ*: 171.9, 166.9, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 156.3, 149.8, 139.4(d, ^1^*J*~FC~ = 226.9 Hz), 131.2(d, ^2^*J*~FC~ = 33.8 Hz), 130.3, 127.0, 115.3, 54.4, 52.0, 49.5, 36.3; IR(KBr, cm^-1^) *ν*: 3271, 1739, 1712, 1661, 1552, 1516, 1451, 1386, 1231, 1164, 778; MS(ESI) *m/z*: 364(M^+^); $\left\lbrack \alpha \right\rbrack_{D}^{17.8}$+16.6 (*c* 1.0, DMF).

(*R*)-ethyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-(4-hydroxyphenyl) propanoate (**2m**). Yield: 70%; m.p. 156-158 °C; ^1^H-NMR(300 MHz) *δ*: 11.82(s, 1H, NH of 5-FU), 9.23(s, 1H, OH), 8.63(d, 1H, NH, *J* = 7.5 Hz), 7.94(d, 1H, FC=CH, ^3^*J*~FH~ = 6.6 Hz), 6.99(d, 2H, Ar-H, *J* = 8.4 Hz), 6.65(d, 2H, Ar-H, *J* = 8.4 Hz), 4.36(dd, 1H, NCH, *J* = 7.5, 6.9 Hz), 4.31(d, 2H, NCH~2~, *J* = 16.8 Hz), 4.02(q, 2H, OCH~2~, *J* = 7.2 Hz), 2.89-2.77(m, 2H, CH~2~Ar, *J* = 7.5, 6.0, 13.8 Hz), 1.10(t, 3H, CH~3~, *J* = 7.2 Hz); ^13C-NMR^(75 MHz) *δ*: 171.4, 166.9, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 156.3, 149.8, 139.4(d, ^1^*J*~FC~ = 228.1 Hz), 131.2(d, ^2^*J*~FC~ = 33.9 Hz), 130.3, 127.0, 115.3, 60.7, 54.4, 49.5, 36.4, 14.1; IR(KBr, cm^-1^) *ν*: 3336, 3065, 2851, 1691, 1532, 1380, 1340, 1220, 801; MS(ESI) *m/z*: 378(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{9.7}$-24.4 (*c* 1.0, DMF).

(2*S,*3*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-methylpentanoate (**2n**). Yield: 70%; m.p. 152-154 °C; ^1^H-NMR(300 MHz) *δ*: 11.82(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.1 Hz), 8.57(d, 1H, NH, *J* = 8.1 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.9 Hz), 4.36(d, 2H, NCH~2~, *J* = 16.8 Hz), 4.25(dd, 1H, NCH, *J* = 8.1, 6.6 Hz), 3.63(s, 3H, OCH~3~), 1.77-1.72(m, 1H, CCH), 1.43-1.09(m, 2H, CCH~2~), 0.84(t, 3H, CH~2~C[H]{.ul}~3~, *J* = 7.2 Hz), 0.83(d, 3H, CHC[H]{.ul}~3~, *J* = 6.9 Hz); ^13C-NMR^(75 MHz) *δ*: 172.0, 167.1, 157.7(d, ^2^*J*~FC~ = 25.7 Hz), 149.8, 139.3(d, ^1^*J*~FC~ = 227.9 Hz), 131.4(d, ^2^*J*~FC~ = 33.8 Hz), 56.6, 52.0, 49.5, 36.9, 24.9, 15.6, 11.3; IR(KBr, cm^-1^) *ν*: 3275, 3083, 2968, 1712, 1666, 1571, 1460, 1378, 1340, 1243, 1149, 976, 700; MS(ESI) *m/z*: 314(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.5}$-3.0 (*c* 0.5, DMF).

(2*S,*3*S*)-methyl 2-(2-5-(fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)acetamido)-3-hydroxybutanoate (**2o**). Yield: 47%; m.p. 207-208 °C; ^1^H-NMR(300 MHz) *δ*: 11.79(d, 1H, NH of 5-FU, ^4^*J*~FH~ = 5.1 Hz), 8.44(d, 1H, NH, *J* = 8.4 Hz), 8.01(d, 1H, FC=CH, ^3^*J*~FH~ = 6.6 Hz), 5.03(d, 1H, OH, *J* = 5.1 Hz), 4.42(dd, 2H, NCH~2~, *J* = 6.6, 16.5 Hz), 4.32(dd, 1H, NCH, *J* = 8.4, 3.3 Hz), 4.15-4.08(m, 1H, C[H]{.ul}OH, *J* = 3.3, 5.1, 6.3 Hz), 1.05(d, 3H, CH~3~, *J* = 6.3 Hz); ^13^C NMR(75 MHz) *δ* 171.0, 167.4, 157.7(d, ^2^*J*~FC~ = 25.6 Hz), 149.8, 139.3(d, ^1^*J*~FC~ = 226.6 Hz), 131.4(d, ^2^*J*~FC~ = 33.5 Hz), 66.5, 58.1, 52.0, 49.6, 20.2; IR(KBr, cm^-1^) *ν*: 3484, 3312, 2977, 1718, 1663, 1558, 1376, 1283, 1238, 1140; MS(ESI) *m/z*: 302(M^-^); $\left\lbrack \alpha \right\rbrack_{D}^{17.6}$-2.0 (*c* 0.1, DMF).

4. Conclusions {#sec4-molecules-14-03142}
==============

A serials of amino acid ester derivatives containing 5-fluorouracil were synthesized by EDC/HOBt method and characterized. The *in vitro* antitumor activity tests indicated that the synthesized compounds had less inhibition rates against HL-60 and BEL-7402 than 5-FU except compound **2m**, which showed more potent inhibitory effect against BEL-7402 than 5-FU. This might be explained by the R configuration of compound **2m** with the moderate rigid framework composed of pyrimidine ring and hydroxyphenyl ring, which may be easily to give 5-fluorouracil.
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![Synthesis of 2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-aceto amino acid ester derivatives **2**.](molecules-14-03142-sch001){#molecules-14-03142-sch001}

![Structural formulae of compounds **2**.](molecules-14-03142-g001){#molecules-14-03142-f001}

molecules-14-03142-t001_Table 1

###### 

Inhibitory rates (%) against HL-60.

  Compounds    Concentration (mol/L)                        
  ------------ ----------------------- ------ ------ ------ ------
  **2a**       2.0                     8.0    9,6    6.9    8.3
  **2b**       3.7                     5.2    6.2    9.7    2.8
  **2c**       33.1                    0.1    9.9    9.8    0
  **2d**       27.3                    0      1.7    0      10.0
  **2e-1**     22.4                    11.2   7.1    4.2    1.2
  **2e-2**     18.5                    15.3   3.4    10.5   0
  **2f-1**     3.3                     10.8   6.6    12.3   0
  **2f-2**     31.8                    9.2    3.7    6.2    0
  **2g**       36.1                    10.0   5.7    5.0    2.5
  **2h**       55.7                    19.6   23.1   2.3    8.6
  **2i**       2.8                     6.7    1.5    8.3    0.6
  **2j**       55.8                    12.8   2.7    5.4    5.9
  **2k-1**     29.2                    0      3.8    8.2    2.4
  **2k-2**     51.2                    15.5   9.8    12.7   8.9
  **2l**       42.4                    7.9    5.2    9.9    5.7
  **2m**       65.1                    0      12.6   13.0   0.3
  **2n**       11.4                    0      0      0      0
  **2o**       22.4                    11.2   7.1    4.2    1.2
  **5-FU**     57.4                    33.5   0      7.0    10.4
  **FT-207**   0                       0      0      0      0

molecules-14-03142-t002_Table 2

###### 

Inhibitory rates (%) against BEL-7402.

  Compounds    Concentration (mol/L)                        
  ------------ ----------------------- ------ ------ ------ ------
  **2a**       0                       0      0      0      0
  **2b**       9.0                     8.1    0      0      1.8
  **2c**       50.0                    13.2   5.7    5.2    0
  **2d**       13.2                    0      0      0      0
  **2e-1**     41.2                    9.7    8.8    8.2    9.1
  **2e-2**     38.4                    9.1    8.8    0      5.3
  **2f-1**     17.4                    10.5   16.6   14.0   4.6
  **2f-2**     41.2                    9.8    0      0      0
  **2g**       36.1                    11.1   7.0    7.4    2.4
  **2h**       52.6                    15.9   2.4    0.7    0
  **2i**       14.5                    8.7    8.0    4.6    11.7
  **2j**       34.0                    9.2    4.1    3.5    5.9
  **2k-1**     35.9                    0      6.9    3.0    0.7
  **2k-2**     22.4                    11.9   7.1    4.2    1.2
  **2l**       36.2                    10.2   4.9    0.5    0
  **2m**       71.7                    68.3   60.4   43.1   24.3
  **2n**       8.2                     4.5    5.2    0      0
  **2o**       9.7                     0      8.8    8.2    9.1
  **5-FU**     72.6                    53.8   35.0   23.8   16.6
  **FT-207**   58.0                    8.1    0      0      0
